Rimegepant is already FDA-approved for acute treatment of migraine and preventive treatment of episodic migraine in adults.

The Mediterranean diet outperforms general healthy eating advice for improving symptoms of irritable bowel syndrome, new data ...

In a groundbreaking study, British scientists have found that the Mediterranean diet could be the most effective way to ...

Among 139 adults with IBS, 62% of those following a Mediterranean diet achieved clinically significant symptom relief (95% CI ...

Irritable bowel syndrome, or IBS, is a chronic disorder of the gastrointestinal system that affects the quality of life in children and adults. Symptoms include varying types of abdominal discomfort ...

Titrated low-dose amitriptyline significantly improved irritable bowel syndrome (IBS) symptoms when used as a second-line treatment in the primary care setting, the randomized ATLANTIS trial showed.

There's growing evidence that a Mediterranean diet can provide relief from symptoms of irritable bowel syndrome (IBS), ...

From abdominal pain and bloating to urgent bathroom trips and constipation, irritable bowel syndrome (IBS) can be a disruptive condition to live with. Fortunately, there are treatments available that ...

For adults with irritable bowel syndrome (IBS), combining a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) and a gluten-free diet (GFD) appears to ...

Tenapanor (Ibsrela) is an FDA-approved medication designed to help manage irritable bowel syndrome with constipation (IBS-C) when other treatments aren’t effective. The medication increases water ...

A study funded by the National Institute of Diabetes and Digestive and Kidney Diseases found that a significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy, ...

There’s no cure for IBS, but medications along with dietary and lifestyle changes can help you prevent flare-ups. Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder without a cure.